The narsoplimab review by the European Medicines Agency’s medicines committee ended with another negative opinion on October 16, 2026, leaving Omeros without the European authorization it sought. The company also announced plans to terminate its compassionate-use program as U.S. commercial demand increases, while pursuing alternative access arrangements for patients in Europe.
Key Takeaways
- CHMP maintained its negative opinion after re-examining the June 2026 outcome.
- Omeros said an expert group requested an external review of individual patient data.
- Existing compassionate-use patients will receive enough medicine to complete treatment.
Table of Contents
- Narsoplimab review raises questions about patient-data assessment
- European commercialization remains conditional
- Patient-access changes accompany supply demand
- Conclusion
Narsoplimab review raises questions about patient-data assessment
The application covers hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, a severe complication of stem cell transplantation. The re-examination did not reverse the Committee for Medicinal Products for Human Use’s earlier unfavorable opinion.
Omeros’ October 16 regulatory announcement describes an eight-member expert group of hematologists, statisticians and transplant physicians, joined by two patient representatives. The group was convened to address a three-part question prepared by CHMP.
Omeros said CHMP’s meeting minutes recorded a recommendation for external experts to review individual patient-level data to better understand treatment response and survival. The company said it submitted substantial patient-level data in August, but CHMP did not provide those data to the expert group.
That account describes Omeros’ concerns about the review process; it does not establish that an external assessment would have changed the regulatory outcome.
| Item | Details |
|---|---|
| Compassionate-use continuity | Patients already receiving treatment will receive sufficient supply to finish their courses. |
| Additional clinical studies | Studies in acute respiratory distress syndrome and prevention of high-risk pediatric TA-TMA are planned to begin later in 2026. |
| Long-acting MASP-2 program | OMS1029 has completed Phase 1 clinical trials. |
European commercialization remains conditional
Narsoplimab is already sold in the United States as YARTEMLEA. The FDA approved it in December 2025 for TA-TMA in adults and children aged two years and older, according to Omeros.
The company commercializes the treatment through its own U.S. field force. Its European strategy is different: Omeros plans to license European Union commercialization rights to a third party if marketing authorization is granted. The negative opinion therefore leaves that licensing strategy conditional rather than ready for implementation.
Omeros said there is no approved therapy for TA-TMA in Europe. Chief Executive Gregory A. Demopulos expressed disappointment with the re-examination process and outcome.
Patient-access changes accompany supply demand
Omeros informed CHMP of its intention to terminate the YARTEMLEA compassionate-use program, citing increasing demand for drug supply in the U.S. commercial market. The announcement described a planned termination, not a completed shutdown.
The company is working to enable fully reimbursed, named-patient access where permitted in Europe and other regions. That effort is separate from securing broad European marketing authorization, and Omeros did not announce that those arrangements were already in place.
Conclusion
The European setback leaves Omeros pursuing patient-access arrangements alongside U.S. commercialization. The next stated development milestone is the planned start of additional clinical studies later in 2026; those starts were not confirmed in the October 16 announcement.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
